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Diltiazem and Hyperglycemia-Coma 
Hyperosmolar nonketotic coma most commonly occurs in the el-
derly patient with heart disease who is receiving long-term diuretic 
or corticosteroid therapy (I). Long-term administration of pro-
pranolol also has been associated with the onset of hyperglycemia 
and diabetic coma (I ,2). A recent case report (3) revealed profound 
hyperglycemia and metabolic acidosis after verapamil overdose. 
We describe an 85 year old woman who developed hyperosmolar 
nonketotic coma after therapeutic doses of diltiazem. She was 
diagnosed as having angina in October 1983. Diltiazem 120 mg/day 
was prescribed in divided doses with satisfactory control. In early 
December 1983 she became comatose. There was no history of 
diabetes mellitus, alcoholism or drug overdose. Examination re-
vealed dehydration, shallow and rapid respirations, hypotension, 
sinus tachycardia and no odor of acetone. Laboratory findings 
revealed hypokalemia, hyperglycemia (glucose 617 mg/dl), gly-
cosuria, hypematremia, hyperosmolarity and metabolic acidosis. 
There was no evidence of ketonuria. Insulin, appropriate fluid and 
electrolyte therapy were administered. She had been receiving no 
medication other than diltiazem, which was discontinued. She 
made a satisfactory recovery and did not need any hypoglycemic 
agent thereafter. Just before hospital discharge, she had a fatal 
myocardial infarction. 
Calcium ions are indispensable to the secretory glandular pro-
cess. Calcium channel blockers, therefore, have been suspected to 
cause endocrine disturbances; they have also been shown to affect 
insulin release in vivo. Furthermore, several in vivo studies have 
demonstrated that calcium channel blockers have an inhibitory 
effect on the beta islet cells of the pancreas and subsequent insulin 
production (4). 
Nifedipine has been shown to induce distinct glucose intoler-
ance. Plasma glucose levels during fasting were reported to in-
crease 10%, whereas basal insulin concentrations were signifi-
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candy reduced; the response to the oral glucose dose showed marked 
impairment of tolerance (5,6). De Marinis and Barbarino (4) also 
discovered that intravenous infusion of verapamil produced a marked 
and significant inhibition of glucose, glucagon and sulfonylurea-
induced increases in serum insulin in nondiabetic patients. Calcium 
channel blockers have been used in patients with islet cell tumors 
who experienced a decrease in the severity and frequency of hy-
poglycemic attacks while autonomous insulin release was inhibit-
ed (7). 
Several reports (3) of severe hyperglycemia and metabolic 
acidosis after verapamil overdose have appeared. Our case con-
firms the extent of deterioration of carbohydrate tolerance in pa-
tients receiving therapeutic doses of a calcium channel blocker. 
Diltiazem, verapamil and nifedipine all must be regarded as dia-
betogenic. It would thus seem necessary to exert caution in using 
all calcium channel blockers in diabetic patients. 
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